Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion type Assertion NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_head.
- NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion description "[We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_provenance.
- NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion evidence source_evidence_literature NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_provenance.
- NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion SIO_000772 16507781 NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_provenance.
- NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion wasDerivedFrom befree-20140225 NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_provenance.
- NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_assertion wasGeneratedBy ECO_0000203 NP608406.RAsQjn2rFFPONhzVXhDsj37YtgC_LZ9HgfmbmJCFAGyUM130_provenance.